Search results
Showing results for
A new statement has been released from Professor Peter Horby and Professor Martin Landray, Chief Investigators of the RECOVERY Trial. RECOVERY was established in March as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. The chief investigators have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.
Chris Paton
BMBS BMedSci MBA DPhil FBCS Chris Paton - Honorary Visiting Scientist
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Ashata Dahal
Ashata Dahal - Public Engagement Manager (OUCRU Nepal)/ DPhil candidate (University of Oxford)
Suchita Shrestha
Suchita Shrestha - Head of the Clinical Trials Unit, OUCRU Nepal
Gisela Robles Aguilar
Gisela Robles Aguilar - Global Burden of Disease Researcher
Rachel Hounsell
Rachel Hounsell - Senior Researcher and Teaching Fellow
Proochista Ariana
- MSc IHTM Executive Team
- MSc IHTM Lecturers
- MSc IHTM advisory committee
- MSc MGH Lecturers
- Principal Investigators
- Research Scientists
Proochista Ariana - Associate Professor
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Kevin Marsh
Kevin Marsh - Professor of Tropical Medicine